Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
CHOP-Style Chemotherapy for Canine Lymphoma: Protocol Discussion Profile
CHOP is a family of veterinary lymphoma protocols built around cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine and prednisone. Exact sequence, dose and duration vary by oncology service and patient.
Read more
Lomustine (CCNU) in Veterinary Oncology: Delayed-Toxicity Safety Profile
Lomustine, also called CCNU, is an oral nitrosourea chemotherapy drug used by veterinary oncologists for selected cancers. Use in dogs and cats is generally extra-label and requires a…
Read more
Cyclophosphamide in Cancer Protocols: Bladder and Marrow Safety
Cyclophosphamide is an alkylating chemotherapy used in selected veterinary protocols, with blood-count, urinary, gastrointestinal, and household-safety considerations.
Read moreChlorambucil: Oral Chemotherapy Is Still Hazardous Medicine
Chlorambucil is an oral alkylating chemotherapy used in selected slow-growing blood cancers and other protocols, with cumulative marrow and handling considerations.
Read moreMelphalan in Veterinary Oncology: Cumulative Marrow-Risk Discussion
Melphalan is an alkylating antineoplastic medicine used in selected veterinary cancers and requires individualized blood-count, gastrointestinal, and handling plans.
Read moreMethotrexate in Veterinary Oncology: Interaction and Organ-Safety Review
Methotrexate is a folate-antagonist antimetabolite with selected veterinary uses and clinically important marrow, gastrointestinal, liver, lung, and interaction considerations.
Read moreMetronomic Chemotherapy: Goal, Evidence, and Handling Boundary
Metronomic therapy uses regularly scheduled cytotoxic medication in selected plans; it remains prescription hazardous-drug treatment and is not simply gentle chemotherapy.
Read moreHome Handling of Oral Chemotherapy and Patient Waste
Families need drug-specific written instructions for receiving, storing, administering, cleaning, laundering, and disposing of chemotherapy and contaminated patient waste.
Read moreNamed profile Temozolomide in Veterinary Oncology: Oral Alkylator and Evidence BoundaryRepresentative category illustration – no product packaging is shown.Temozolomide in Veterinary Oncology: Oral Alkylator and Evidence Boundary
temozolomide is covered as triazene antineoplastic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more
Named profile 5-Fluorouracil in Veterinary Oncology: Critical Feline Toxicity WarningRepresentative category illustration – no product packaging is shown.5-Fluorouracil in Veterinary Oncology: Critical Feline Toxicity Warning
5-fluorouracil (5-FU) is covered as fluoropyrimidine antimetabolites; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read moreNamed profile Mitotane in Canine Adrenal Disease and Adrenocortical TumoursRepresentative category illustration – no product packaging is shown.Mitotane in Canine Adrenal Disease and Adrenocortical Tumours
mitotane (o,p′-DDD) is covered as adrenocorticolytic agents; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read moreNamed profile Hydroxyurea in Veterinary Oncology: Myeloproliferative-Disease ProfileRepresentative category illustration – no product packaging is shown.Hydroxyurea in Veterinary Oncology: Myeloproliferative-Disease Profile
hydroxyurea is covered as ribonucleotide-reductase inhibitors; hazardous antineoplastic medicine, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.
Read more